Choose a language and wait for the translated text.
Shots:
The US FDA has granted accelerated approval to GSK’s Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib as their only prior ALK TKI, or with ≥2 prior ALK TKIs and platinum-based chemotherapy
Approval was based on the P-I/II (ALKOVE-1) trial: ORR was 49% (33/67) after alectinib alone (DOR ≥6 mos in 76% and ≥12 mos in 52% of responders) and 32% (50/155) after ≥2 prior ALK TKIs plus chemotherapy (DOR ≥6 mos in 69% and ≥12 mos in 51%); intracranial ORR was 55% and 26%, respectively, in pts with baseline CNS mets
The most common (≥20%) AEs incl. hepatotoxicity, which drove most of the 5% permanent discontinuations; approval came ahead of the Nov 27, 2026 target date, and Nelkarmi (from the Nuvalent acquisition) is also in P-III (ALKAZAR) for TKI-naïve disease
Ref: GSK | Image: GSK | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The US FDA Grants Accelerated Approval to GSK’s Nelkarmi (Neladalkib) for Previously Treated ALK-Positive NSCLC appeared first on PharmaShots.
The US FDA Grants Accelerated Approval to GSK’s Nelkarmi (Neladalkib) for Previously Treated ALK-Positive NSCLC | PharmaVoice